Skip to main content
Top
Published in: BMC Medicine 1/2013

Open Access 01-12-2013 | Research article

Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy

Authors: Bernardo Costa, Francisco Barrio, Josep L Piñol, Joan J Cabré, Xavier Mundet, Ramon Sagarra, Jordi Salas-Salvadó, Oriol Solà-Morales, the DE-PLAN-CAT/PREDICE Research Group

Published in: BMC Medicine | Issue 1/2013

Login to get access

Abstract

Background

To investigate differences in the performance of the Finnish Diabetes Risk Score (FINDRISC) as a screening tool for glucose abnormalities after shifting from glucose-based diagnostic criteria to the proposed new hemoglobin (Hb)A1c-based criteria.

Methods

A cross-sectional primary-care study was conducted as the first part of an active real-life lifestyle intervention to prevent type 2 diabetes within a high-risk Spanish Mediterranean population. Individuals without diabetes aged 45-75 years (n = 3,120) were screened using the FINDRISC. Where feasible, a subsequent 2-hour oral glucose tolerance test and HbA1c test were also carried out (n = 1,712). The performance of the risk score was calculated by applying the area under the curve (AUC) for the receiver operating characteristic, using three sets of criteria (2-hour glucose, fasting glucose, HbA1c) and three diagnostic categories (normal, pre-diabetes, diabetes).

Results

Defining diabetes by a single HbA1c measurement resulted in a significantly lower diabetes prevalence (3.6%) compared with diabetes defined by 2-hour plasma glucose (9.2%), but was not significantly lower than that obtained using fasting plasma glucose (3.1%). The FINDRISC at a cut-off of 14 had a reasonably high ability to predict diabetes using the diagnostic criteria of 2-hour or fasting glucose (AUC = 0.71) or all glucose abnormalities (AUC = 0.67 and 0.69, respectively). When HbA1c was used as the primary diagnostic criterion, the AUC for diabetes detection dropped to 0.67 (5.6% reduction in comparison with either 2-hour or fasting glucose) and fell to 0.55 for detection of all glucose abnormalities (17.9% and 20.3% reduction, respectively), with a relevant decrease in sensitivity of the risk score.

Conclusions

A shift from glucose-based diagnosis to HbA1c-based diagnosis substantially reduces the ability of the FINDRISC to screen for glucose abnormalities when applied in this real-life primary-care preventive strategy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberti KG, Zimmet P, Shaw J: International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007, 24: 451-463.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007, 24: 451-463.CrossRefPubMed
2.
go back to reference Schwarz PE, Li J, Lindström J, Tuomilehto J: Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009, 41: 86-97. 10.1055/s-0028-1087203.CrossRefPubMed Schwarz PE, Li J, Lindström J, Tuomilehto J: Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009, 41: 86-97. 10.1055/s-0028-1087203.CrossRefPubMed
3.
go back to reference American Diabetes Association Position Statement: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 33: S62-S69.CrossRef American Diabetes Association Position Statement: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 33: S62-S69.CrossRef
4.
go back to reference Bloomgarden ZT: A1C: recommendations, debates, and questions. Diabetes Care. 2009, 32: e141-147. 10.2337/dc09-zb12.CrossRefPubMed Bloomgarden ZT: A1C: recommendations, debates, and questions. Diabetes Care. 2009, 32: e141-147. 10.2337/dc09-zb12.CrossRefPubMed
5.
go back to reference Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001, 344: 1343-1392. 10.1056/NEJM200105033441801.CrossRefPubMed Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001, 344: 1343-1392. 10.1056/NEJM200105033441801.CrossRefPubMed
6.
go back to reference Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346: 393-403.CrossRefPubMedCentral Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346: 393-403.CrossRefPubMedCentral
7.
go back to reference Costa B, Barrio F, Cabré JJ, Piñol JL, Cos X, Solé C, Bolíbar B, Basora J, Castell C, Solà-Morales O, Salas-Salvadó J, Lindström J, Tuomilehto J, DE-PLAN-CAT Research Group: Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia. 2012, 55: 1319-1328. 10.1007/s00125-012-2492-6.CrossRefPubMed Costa B, Barrio F, Cabré JJ, Piñol JL, Cos X, Solé C, Bolíbar B, Basora J, Castell C, Solà-Morales O, Salas-Salvadó J, Lindström J, Tuomilehto J, DE-PLAN-CAT Research Group: Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia. 2012, 55: 1319-1328. 10.1007/s00125-012-2492-6.CrossRefPubMed
8.
go back to reference Lindström J, Tuomilehto J: The Diabetes Risk Score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003, 26: 725-731. 10.2337/diacare.26.3.725.CrossRefPubMed Lindström J, Tuomilehto J: The Diabetes Risk Score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003, 26: 725-731. 10.2337/diacare.26.3.725.CrossRefPubMed
9.
go back to reference Schwarz PE, Lindström J, Kissimova-Skarbek K, Szybinski Z, Barengo NC, Peltonen M, Tuomilehto J, on behalf of the DE-PLAN project: The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008, 116: 167-172. 10.1055/s-2007-992115.CrossRefPubMed Schwarz PE, Lindström J, Kissimova-Skarbek K, Szybinski Z, Barengo NC, Peltonen M, Tuomilehto J, on behalf of the DE-PLAN project: The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008, 116: 167-172. 10.1055/s-2007-992115.CrossRefPubMed
11.
go back to reference Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M, Paulweber M, Stadlmayr A, Kedenko L, Katsilambros N, Makrilakis K, Kamenov Z, Evans P, Gilis-Januszewska A, Lalic K, Jotic A, Djordevic P, Dimitrijevic-Sreckovic V, et al: A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010, 42 (Suppl 1): S3-S36.CrossRefPubMed Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M, Paulweber M, Stadlmayr A, Kedenko L, Katsilambros N, Makrilakis K, Kamenov Z, Evans P, Gilis-Januszewska A, Lalic K, Jotic A, Djordevic P, Dimitrijevic-Sreckovic V, et al: A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010, 42 (Suppl 1): S3-S36.CrossRefPubMed
12.
go back to reference Lindström J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Pölönen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, et al: Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res. 2010, 42 (Suppl 1): S37-S55.CrossRefPubMed Lindström J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Pölönen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, et al: Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res. 2010, 42 (Suppl 1): S37-S55.CrossRefPubMed
13.
go back to reference The International Expert Committee: International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334.CrossRefPubMedCentral The International Expert Committee: International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334.CrossRefPubMedCentral
14.
go back to reference Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Davies MJ, Khunti K: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007, 334: 229-237.CrossRef Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Davies MJ, Khunti K: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007, 334: 229-237.CrossRef
15.
go back to reference Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in non-diabetic adults. N Engl J Med. 2010, 362: 800-811. 10.1056/NEJMoa0908359.CrossRefPubMedPubMedCentral Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in non-diabetic adults. N Engl J Med. 2010, 362: 800-811. 10.1056/NEJMoa0908359.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, Imperatore G, Williams DE, Albright AL: A1c level and future risk of diabetes: a systematic review. Diabetes Care. 2010, 33: 1665-1673. 10.2337/dc09-1939.CrossRefPubMedPubMedCentral Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, Imperatore G, Williams DE, Albright AL: A1c level and future risk of diabetes: a systematic review. Diabetes Care. 2010, 33: 1665-1673. 10.2337/dc09-1939.CrossRefPubMedPubMedCentral
17.
go back to reference Buijsse B, Simmons RK, Griffin SJ, Schulze MB: Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011, 33: 46-62. 10.1093/epirev/mxq019.CrossRefPubMedPubMedCentral Buijsse B, Simmons RK, Griffin SJ, Schulze MB: Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011, 33: 46-62. 10.1093/epirev/mxq019.CrossRefPubMedPubMedCentral
18.
go back to reference Collins GS, Mallett S, Omar O, Yu L: Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Medicine. 2011, 9: 103-10.1186/1741-7015-9-103. doi: 10.1186/1741-7015-9-103CrossRefPubMedPubMedCentral Collins GS, Mallett S, Omar O, Yu L: Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Medicine. 2011, 9: 103-10.1186/1741-7015-9-103. doi: 10.1186/1741-7015-9-103CrossRefPubMedPubMedCentral
19.
go back to reference Noble D, Mathur R, Dent T, Meads C, Greenhalgh T: Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011, 343: d7163-10.1136/bmj.d7163. doi: 10.1136/bmj.d7163CrossRefPubMedPubMedCentral Noble D, Mathur R, Dent T, Meads C, Greenhalgh T: Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011, 343: d7163-10.1136/bmj.d7163. doi: 10.1136/bmj.d7163CrossRefPubMedPubMedCentral
20.
go back to reference Ley SH, Harris SB, Mamakeesick M, Noon T, Fiddler E, Gittelsohn J, Wolever TM, Connelly PW, Hegele RA, Zinman B, Hanley AJ: Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ. 2009, 180: 617-624. 10.1503/cmaj.080972.CrossRefPubMedPubMedCentral Ley SH, Harris SB, Mamakeesick M, Noon T, Fiddler E, Gittelsohn J, Wolever TM, Connelly PW, Hegele RA, Zinman B, Hanley AJ: Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ. 2009, 180: 617-624. 10.1503/cmaj.080972.CrossRefPubMedPubMedCentral
21.
go back to reference Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Saloranta C, Tuomi T, Groop L, Botnia Study Group: Genetic prediction of future type 2 diabetes. PLoS Med. 2005, 2: e345-10.1371/journal.pmed.0020345.CrossRefPubMedPubMedCentral Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Saloranta C, Tuomi T, Groop L, Botnia Study Group: Genetic prediction of future type 2 diabetes. PLoS Med. 2005, 2: e345-10.1371/journal.pmed.0020345.CrossRefPubMedPubMedCentral
22.
go back to reference Guasch-Ferré M, Bulló M, Costa B, Martínez-Gonzalez MÁ, Ibarrola-Jurado N, Estruch R, Barrio F, Salas-Salvadó J, PREDI-PLAN investigators: A risk score to predict type 2 diabetes mellitus in an elderly Spanish Mediterranean population at high cardiovascular risk. PLoS One. 2012, 7: e33437-10.1371/journal.pone.0033437.CrossRefPubMedPubMedCentral Guasch-Ferré M, Bulló M, Costa B, Martínez-Gonzalez MÁ, Ibarrola-Jurado N, Estruch R, Barrio F, Salas-Salvadó J, PREDI-PLAN investigators: A risk score to predict type 2 diabetes mellitus in an elderly Spanish Mediterranean population at high cardiovascular risk. PLoS One. 2012, 7: e33437-10.1371/journal.pone.0033437.CrossRefPubMedPubMedCentral
23.
go back to reference Rautio N, Jokelainen J, Oksa H, Saaristo T, Peltonen M, Niskanen L, Puolijoki H, Vanhala M, Uusitupa M, Keinänen-Kiukaanniemi S, FIN-D2D Study Group: Socioeconomic position and effectiveness of lifestyle intervention in prevention of type 2 diabetes: one-year follow-up of the FIN-D2D project. Scand J Public Health. 2011, 39: 561-570. 10.1177/1403494811408482.CrossRefPubMed Rautio N, Jokelainen J, Oksa H, Saaristo T, Peltonen M, Niskanen L, Puolijoki H, Vanhala M, Uusitupa M, Keinänen-Kiukaanniemi S, FIN-D2D Study Group: Socioeconomic position and effectiveness of lifestyle intervention in prevention of type 2 diabetes: one-year follow-up of the FIN-D2D project. Scand J Public Health. 2011, 39: 561-570. 10.1177/1403494811408482.CrossRefPubMed
24.
go back to reference Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N: Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011, 37: 144-151. 10.1016/j.diabet.2010.09.006.CrossRefPubMed Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N: Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011, 37: 144-151. 10.1016/j.diabet.2010.09.006.CrossRefPubMed
25.
go back to reference Vermunt PW, Milder IE, Wielaard F, Baan CA, Schelfhout JD, Westert GP, van Oers HA: Implementation of a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention delivery. BMC Fam Pract. 2012, 13: 79-10.1186/1471-2296-13-79.CrossRefPubMedPubMedCentral Vermunt PW, Milder IE, Wielaard F, Baan CA, Schelfhout JD, Westert GP, van Oers HA: Implementation of a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention delivery. BMC Fam Pract. 2012, 13: 79-10.1186/1471-2296-13-79.CrossRefPubMedPubMedCentral
26.
go back to reference Costa B, Barrio F, Cabré JJ, Piñol JL, Cos X, Solé C, Bolibar B, Castell C, Lindström J, Barengo N, Tuomilehto J, DE-PLAN-CAT Research Group: Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. Diabet Med. 2011, 28: 1234-1237. 10.1111/j.1464-5491.2011.03304.x.CrossRefPubMed Costa B, Barrio F, Cabré JJ, Piñol JL, Cos X, Solé C, Bolibar B, Castell C, Lindström J, Barengo N, Tuomilehto J, DE-PLAN-CAT Research Group: Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. Diabet Med. 2011, 28: 1234-1237. 10.1111/j.1464-5491.2011.03304.x.CrossRefPubMed
27.
go back to reference Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ: Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study. Diabet Med. 2012, 29: 893-904. 10.1111/j.1464-5491.2012.03609.x.CrossRefPubMedPubMedCentral Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ: Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study. Diabet Med. 2012, 29: 893-904. 10.1111/j.1464-5491.2012.03609.x.CrossRefPubMedPubMedCentral
Metadata
Title
Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy
Authors
Bernardo Costa
Francisco Barrio
Josep L Piñol
Joan J Cabré
Xavier Mundet
Ramon Sagarra
Jordi Salas-Salvadó
Oriol Solà-Morales
the DE-PLAN-CAT/PREDICE Research Group
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-11-45

Other articles of this Issue 1/2013

BMC Medicine 1/2013 Go to the issue